Development of autogenous vaccines for the control of amoebic gill disease in farmed Atlantic salmon

该项目汇集了斯特林大学水产养殖研究所的鱼类健康和疫苗学专业知识、专门生产自体疫苗的中小企业Ridgeway生物制品有限公司以及苏格兰最大的鲑鱼生产商Marine Harvest的水产养殖生产知识，以开发和现场试验控制养殖鲑鱼阿米巴吉尔病（AGD）的疫苗。目标是开发针对AGD的农场特异性疫苗，尽管迫切需要这种疾病，但目前还没有疫苗。2011年，这种疾病首次给英国鲑鱼养殖业带来了重大问题，迄今为止，英国和爱尔兰的养殖业损失了5000万英镑。基于农场特有的种子分离物的自体疫苗，可以根据兽医管理局控制的特定法规生产。这种疫苗可以在没有针对特定病原体的完全许可疫苗的情况下生产和供应。面对AGD等新出现的疾病威胁，这类产品具有迅速开发和部署的潜力。

This project brings together fish health and vaccinology expertise from the University of Stirling's Institute of Aquaculture, Ridgeway Biologicals Ltd., an SME specialising in the production of autogenous vaccines, and aquaculture production knowledge from Marine Harvest, Scotland's biggest salmon producer, to develop and field test vaccines for the control of Amoebic Gill Disease (AGD) in farmed salmon. The objective is to develop farm-specific vaccines for AGD, a disease for which there is no vaccine despite an urgent need. This disease first caused major problems for the UK salmon aquaculture industry in 2011, costing UK and Irish industries £50 million to date. Autogenous vaccines, based on farm-specific seed isolates, can be produced under specific regulations, controlled by the Veterinary Medicines Directorate. Such vaccines can be manufactured and supplied in the absence of any fully licensed vaccine being available for a specific pathogen. Such products have the potential to be developed and deployed rapidly in the face of emerging disease threats such as AGD.